Treatment of Advanced Emphysema with Emphysematous Lung Sealant (AeriSeal (R))

Background: This report summarizes initial tests of an emphysematous lung synthetic polymer sealant (ELS) designed to reduce lung volume in patients with advanced emphysema. Objectives: The primary study objective was to define a therapeutic strategy to optimize treatment safety and effectiveness. Methods: ELS therapy was administered bronchoscopically to 25 patients with heterogeneous emphysema in an open-label, noncontrolled study at 6 centers in Germany. Treatment was performed initially at 2-4 subsegments. After 12 weeks, patients were eligible for repeat therapy to a total of 6 sites. Safety and efficacy were assessed after 6 months. Responses were evaluated in terms of changes from baseline in lung physiology, functional capacity, and health-related quality of life. Follow-up is available for 21 of 25 patients. Results: Treatment was well tolerated. There were no treatment-related deaths (i.e. within 90 days of treatment), and an acceptable short-and long-term safety profile. Physiological and clinical benefits were observed at 24 weeks. Efficacy responses were better among Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage III patients {[}n = 14; change in residual volume/total lung capacity (Delta RV/TLC) = -7.4 +/- 10.3%; Delta forced expiratory volume in 1 s (Delta FEV(1)) = +15.9 +/- 22.6%; change in forced vital capacity (Delta FVC) = +24.1 +/- 22.7%; change in carbon monoxide lung diffusion capacity (Delta DLCO) = +19.3 +/- 34.8%; change in 6-min walk test (Delta 6MWD) = +28.7 +/- 59.6 m; change in Medical Research Council Dyspnea (Delta MRCD) score = -1.0 +/- 1.04 units; change in St. George's Respiratory Questionnaire (Delta SGRQ) score = -9.9 +/- 15.3 units] than for GOLD stage IV patients (n = 7; Delta RV/TLC = -0.5 +/- 6.4%; Delta FEV 1 = +2.3 +/- 12.3%; Delta FVC = +2.6 +/- 21.1%; Delta DLCO = -2.8 +/- 17.2%; Delta 6MWD = +28.3 +/- 58.4 m; Delta MRCD = 0.3 +/- 0.81 units; Delta SGRQ = -6.7 +/- 7.0 units). Conclusions: ELS therapy shows promise for treating patients with advanced heterogeneous emphysema. Additional studies to assess responses in a larger cohort with a longer follow-up are warranted. Copyright (C) 2011 S. Karger AG, Base

Pulmonary changes associated with cutaneous melanin pigmentation

USMF ʺNicolae Testemițanuʺ, Departamentul de medicină internă, disciplina pneumologie/alergologie, Chișinău, Republica Moldov

Tree in bud heralds not only the spring

Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Departamentul Medicină Internă, Disciplina Pneumologie și Alergologie, Chișinău, Republica Moldov

Multiple lung involvements – a landmark in immunocompromised patient

Disciplina de pneumologie şi alergologie, Departamentul de medicină internă, Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica Moldova, Institutul de Ftiziopneumologie „Chiril Draganiuc”, Chişinău, Republica Moldov

Einfluss der Art der Materialgewinnung auf die Diagnosefindung in der Lungenpathologie

Das Ziel der Arbeit ist die Darstellung der Möglichkeiten der Kryobiopsien für die Diagnostik von Lungenerkrankungen und Pleuraerkrankungen. Es wurde zunächst gezeigt, dass die transbronchialen Kryobiopsien einen deutlichen morphologischen Unterschied gegenüber den konventionellen transbronchialen Biopsien zeigen, indem sie größer sind und häufiger alveoläres Gewebe enthalten. Entnahmebedingte Artefakte des alveolären Gewebes zeigten sich nicht. Untersucht wurden Patientenkollektive mit Krebserkrankungen sowie mit interstitiellen Lungenerkrankungen. In beiden Gruppen zeigt sich eine deutliche Steigerung der diagnostischen Ausbeute. Bei den pleuralen Läsionen konnte mindestens eine Gleichwertigkeit der Methode der Kryobiopsie der Pleura mit einer flexiblen Zangenbiopsie gezeigt werden. Die letzte vorgelegte Arbeit zeigt die erste Beschreibung einer durch Kryobiopsie gesicherten diffusen idiopathischen Hyperplasie der neuroendokrinen Zellen (DIPNECH). Insgesamt zeigt sich eine gute Einsetzbarkeit der Methode bei allen Lungen- und Pleuraerkrankungen.The aim of this work is to present a variety of cryobiopsies for the diagnosis of pulmonary and pleural diseases. The first paper describes a distinct morphologic difference between cryobiopsies and traditional transbronchial biopsies. Cryobiopsies reveal to be larger, contain more common alveolar tissue, which does not show any artefacts. The following analyses included patient groups with cancer and interstitial lung diseases. Both groups show a higher diagnostic yield concerning the specific disease. For the pleural lesions it could be demonstrated that there is at least a diagnostic equivalence between cryobiopsy and flexible thoracosopy. Finally, the last paper is a first case report of a cryobiopsy-diagnosed diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH). Altogether, the method presents itself suitable for application in all groups of lung and pleural diseases

Multicentric vascular neoplasm

Universitatea de Stat de Medicină și Farmacie „Nicolae Testemiţanu”, Departamentul Medicină Internă, Disciplina Pneumologie și Alergologie, Chișinău, Republica Moldov

Constellations of nodular lesions

Disciplina pneumologie şi alergologie, Departamentul de medicină internă, Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica Moldova, Institutul de Ftiziopneumologie „Chiril Draganiuc”, Chişinău, Republica Moldov

Verum aut Falsum Cavitas

Disciplina de pneumologie și alergologie, Universitatea de Stat de Medicină și Farmacie „Nicolae Testemţanu”, Chișinău, Republica Moldovahttps://stiinta.usmf.md/sites/default/files/2018-09/MJHS%20nr.1_2016.pd

ARIA 2016 : Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, EU Structural and Development Fund Languedoc-Roussillon, ARIA.Peer reviewedPublisher PD